PhotoPharmics is a clinical-stage medical device company developing next-generation treatments for neurodegenerative disorders through the eyes.
Location: United States, Utah, American Fork
Employees: 1-10
Phone: +1 801-770-6960
Total raised: $6M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Kickstart | kickstartf... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.04.2025 | Series B | $6M | - |
Mentions in press and media 14
| Date | Title | Description |
| 22.04.2025 | Illuminating Hope: PhotoPharmics' Breakthrough in Parkinson’s Treatment | In the world of medical innovation, light can be a beacon of hope. PhotoPharmics, a trailblazer in specialized light therapy, has just secured a significant $6 million in funding. This investment is not just a financial boost; it’s a lifeli... |
| 21.04.2025 | PhotoPharmics Secures $6M for Parkinson’s Light Therapy Trial | What You Should Know: – PhotoPharmics, a leader in specialized light therapy for neurodegenerative diseases, today announced the close of its oversubscribed $6 million Series B extension. – The round was led by Kickstart Fund with participa... |
| 18.04.2025 | PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device | Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200 enrolled participants This funding gives us the runway we need to complete our FDA research, build strategic partnerships, and ensure the best possible outcomes for... |
| 08.04.2025 | PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial | Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and inclusion in therapeutic research There’s a large segment of the Parkinson’s community that is still struggling with persistent motor and non-motor sy... |
| 07.02.2025 | PhotoPharmics Achieves 50% Enrollment in Pioneering Phase 3 Parkinson’s Trial | Advancing Light Therapy Research to Enhance Quality of Life for Parkinson’s Patients This trial is important because it addresses the often-overlooked aspects of Parkinson’s disease—non-motor symptoms that severely impact daily life but hav... |
| 31.01.2025 | PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board | Dr. Hauser’s dedication to patient-centered care and his expertise in advancing scientific discovery make him uniquely qualified to guide us through this next chapter.” — Kent Savage, CEO LEHI, UT, UNITED STATES, January 31, 2025 /EINPressw... |
| 05.12.2024 | PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinson’s Trial at PSG Annual Meeting | Presentation to Highlight Feasibility and Interest in Decentralized Home-Based Phase 3 Trial We are excited to share the success and insights of this fully remote trial design.” — Kent Savage, CEO SALT LAKE CITY, UT, UNITED STATES, December... |
| 22.06.2023 | Celeste® Light for PD Trial to be Presented at World Parkinson’s Congress | PhotoPharmics to showcase groundbreaking research at the prestigious international event July 5-7, 2023 Presenting at the World Parkinson Congress allows our team to collaborate with leading researchers and potential trial participants in a... |
| 10.05.2023 | PhotoPharmics to Present at MTI All Stars Investor Showcase | Kent Savage, CEO of PhotoPharmics DeviceTalks in Boston on May 10-11 to feature pitches from PhotoPharmics and other leading startups We’re pleased to present the exciting developments at PhotoPharmics at DeviceTalks and be recognized for o... |
| 15.09.2022 | Recruitment for Non-Invasive Parkinson’s Pivotal Study Slated for December | Non-invasive Parkinson’s therapeutic device moves one step closer to FDA clearance, with important potential non-motor and motor improvements for patients. Demand for Celeste from people with Parkinson’s and their care partners has increase... |
Show more